Bullet Dodged: 2 High-Profile Stocks That Tanked This Year

Investors who passed up on the Canopy Growth stock and Aurora Cannabis stock are fortunate. Both high-profile names lost steam after a roaring start in 2021. The weed stocks remain speculative bets.

| More on:
Cannabis stocks have fallen.
You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

The 2020 global pandemic opened buying opportunities in the TSX, with many high-profile stocks trading at deep discounts. While quite a number are delivering positive returns in 2021, a select few are tanking. You’re fortunate if you did not take positions in them yet, or you would have lost money as of this writing.

Canopy Growth (TSX:WEED)(NYSE:CGC) and Aurora Cannabis (TSX:ACB)(NYSE:ACB), industry leaders in the marijuana sector, seem ready for a breakout following the U.S. presidential elections in November 2020. However, both weed stocks are in a tailspin in late February 2021.

From heavy cannabis producer to a CPG company

Shares of Canopy Growth soared to $66.21 on February 10, 2021, only to slide 29% to $46.68 on February 22, 2021. Still, current investors are up 39% on optimism the federal legalization of marijuana in the U.S. will come soon.

Valuations of cannabis companies soared like crazy when Canada legalized in 2018. However, the sector’s boom did not happen, that it became unattractive ever since. The election of Joe Biden as the 46th President of the United States pushed weed stocks, including Canopy Growth, back in the limelight.

Key U.S. Senate leaders met with marijuana stakeholders in early February 2021. Senate Majority Leader Chuck Schumer, along with Senators Ron Wyden and Cory Booker, gathered feedback from various advocacy groups. After the discussions, the three senators plan to unveil draft reform legislation early this year.

Meanwhile, Canopy Growth laid off workers, shut down two massive greenhouses, and announced an $800 million write down in the next quarter. According to Canopy CEO David Klein, the company is right-sizing and improving financial performance.

For the largest shareholder, Constellation Brands, the sweeping overhaul should transform Canopy Growth from a startup, heavy cannabis producer to a basic stock standard consumer packaged goods CPG) company.

Cash burn concerns

Aurora Cannabis shares rose 21% to $23.96 on February 10, 2021, but have fallen since. As of February 22, 2021, the share price is down 38% to $14.83. However, current investors remain up by 40% year to date.

The $2.92 billion cannabis producer is struggling to reach the road to long-term profitability. In Q2 fiscal 2021 (quarter ended December 31, 2020), Aurora’s total net revenue increased by 23% to $67.6 million versus Q2 fiscal 2020. However, the net loss was a wider-than-expected $231 million. Notably, medical marijuana net revenue increased by 42%.

According to Aurora CEO Miguel Martin, the quarterly results were excellent. The initial rollouts of concentrates and vape products supported the core revenue strength in medical and consumer. However, many weed stocks are on fire in 2021 as Reddit traders that propelled GameStop are also moving to the cannabis space.

Some analysts worry about the continuing cash burn of Aurora. For now, the cannabis stock is speculative, and permanent gains are contingent on the full federal legalization of marijuana in the U.S. It might be better to sell the Aurora today before it tanks further.

Fragile sector

Canopy Growth and Aurora Cannabis are the leading weed stocks. However, they are not necessarily solid investment choices if you were to bet your money. The coming merger of Aphria and Tilray would create a powerhouse and the world’s largest cannabis company. It’s hard to pick a winner as the sector remains fragile.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Constellation Brands.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »